Founder and Managing Partner
Vic Lee is the founder and managing partner of Virtus Inspire Ventures. Vic is one of the founders and former senior executive vice president of Tencent, the largest Internet company in China with a market value of about USD 500 billion. He joined Tencent in 1999 and was responsible for planning, construction and managing the operation platforms, including technical architecture, information security, payment settlements, business intelligence, sales channel connection, fundamental IT, applications maintenance, and customer services. From 2010 to 2012, Vic was in charge of the Company’s online search businesses. After leaving Tencent in 2012, he began to invest in technology companies in the US, Israel, and China. Vic was recognized as the "China Top CIO" by 'CEO & CIO China' magazine.
Dr. Tianhong Xu is a partner of Virtus Inspire Ventures. Dr. Xu's life science experience spanned over 15 years as a venture capitalist, UN officer, entrepreneur, research and clinical doctor. He focuses on investments in the medical device, biotech, and healthcare service space. He was a Partner at WI Group and Vangoo Capital, responsible for MedTech investment. Previously, he was a Medical Industry Expert for the United Nations-Industrial Development Organization (UNIDO), where he directed the upgrade of medical industrial clusters in China through investment promotion, technology transfer, and management consulting. He was co-founders of two gene diagnosis and personalized medicine companies. Prior to that, he was a clinical doctor at Renji Hospital in China. He earned his Ph.D. in Molecular and Human Genetics from Baylor College of Medicine in Houston, Texas, and MD from Fudan University, Shanghai, China.
William Deng received a bachelor degree in engineering from China Pharmaceutical University, a master degree in economics from Shanghai University of Finance and Economics. With more than 18-year healthcare industrial working experience in China, he has served Xi 'an Janssen, Medtronic, Roche, AstraZeneca, Citic Guojian companies. Currently, he is focusing on investment in the healthcare industry.
Adam Liu received a master of finance from Peking University, and a bachelor of Hunan University of Traditional Chinese Medicine, and now is a doctoral student in management from Beijing University of Aeronautics and Astronautics. He used to be the head of the pharmaceutical industry of Pacific Securities and Founder Securities Research Institute and a member of the investment bank core committee. He once worked in the Capital Medical Group as the chief supervisor of the hospital, a practicing physician, the managing director of an investment company, and the person in charge of business planning of a medical device company. Currently, he is mainly responsible for medical technology projects.
Yankor Huang graduated from Zhejiang Medical University Hangzhou Branch. He has 20 years of industry experience in the field of medical equipment in China. He has served Johnson & Johnson, Stryker, Braun, Olympus and other famous medical companies, responsible for the operation and management of independent related business departments, and is currently responsible for cross-border medical technology investment and business operations of the post-investment projects.
Senior Investment Manager
With over 7 years of experience in IT companies such as Huawei and WindRiver, Mason Meng focuses on investments in the AI & WEB3.0 sector. Mason received a bachelor degree in Computer Science at Huazhong University of Science and Technology, and also an MBA from China Europe International Business School.
Senior Investment Manager
Graduated from Shanghai Jiao Tong University, majoring in Animal Biotechnology and Finance, and graduated from the full-time MBA program in China Europe International Business School. Over 10-years working experience in the venture capital industry, focusing on industry research and investment opportunities mining in the field of life science and biotechnology.
Mia Zhou graduated from University of Southern California, School of Pharmacy. Once worked in Sinopharm Capital Innovation Fund and Overseas Fund, Cowin Capital and IQVIA management consulting, she accumulated rich experience in overseas innovative drug investment and provided strategic consulting for multinational pharmaceutical companies. She is currently responsible for investment in innovative medicine and biotechnology.
Mark Wu holds a bachelor degree in finance from Jilin University and an MBA from China Europe International Business School. He has 13 years of work experience in the field of corporate financial management and investment, and has experience in pre-investment due diligence and post-investment integration in many companies. Currently, he is mainly responsible for post-investment project operation and pre-investment due diligence.
Risk Control Manager
Temperance Yang has served Ericsson, Bank of China and other companies, and is currently responsible for the whole process risk control and other related work.